← Back to Home

Dismantling the Immune Shield of Cancer Cells and HIV: Experimental Antibodies Target HLA-E

A set of engineered antibodies can release the brakes on immune cells while also marking targets for attack. Cell and mouse experiments provide preliminary support, but healthy tissues that also carry HLA-E will be central to safety testing.

By SURL BioNews

The immune system must know when to spare healthy cells, but cancer cells and virus-infected cells can also exploit this protective mechanism. A Duke University research team has designed a set of antibodies aimed at dismantling the immune shield shared by both. In experiments, the antibodies enhanced immune cells’ ability to kill tumors and HIV-infected cells and also showed antitumor activity in mice.

Duke University School of Medicine presented the findings on October 15; the paper was published in *Science Translational Medicine* on September 16, 2026. The research targets the complex formed by HLA-E and a class of short, nine-amino-acid peptides called VL9. This complex can bind to the inhibitory receptor NKG2A/CD94 on the surface of immune cells, sending a signal that suppresses their attack response.

Combining structure-guided design with high-throughput screening, the team produced antibodies that bind tightly to HLA-E–VL9. These antibodies have two complementary effects: they block inhibitory signals, allowing natural killer cells (NK cells) and CD8⁺ T cells to exert greater killing activity; antibodies attached to target cells can also prompt NK cells to attack through antibody-dependent cellular cytotoxicity.

In the cancer experiments, researchers used human tumor cells carrying HLA-E–VL9 and tested the antibodies in a mouse model. The results showed that the antibodies enhanced the tumor-killing ability of the human NK cell line NK-92, supporting the potential to intervene in this immune checkpoint pathway in vivo. However, this remains a model composed of human tumor cells and experimental immune cells, and the findings cannot yet be used to infer treatment responses in cancer patients.

The HIV evidence came from in vitro experiments. The team found that primary human CD4⁺ T cells could display HLA-E–VL9 on their surfaces after HIV infection. When the antibodies bound to it, they promoted NK-cell clearance of infected cells. The antibodies also enhanced the killing activity of another population of CD8⁺ T cells: these cells carry NKG2A/CD94 and can recognize fragments derived from the HIV Rev protein that are presented by HLA-E.

The convergence of these two lines of research makes HLA-E a candidate therapeutic target linking tumor and viral immune evasion. However, killing infected cells in vitro does not mean that persistent HIV reservoirs in the human body can already be eliminated; the mouse tumor experiments also cannot establish how long the effects might last. The current results support a direction for further development, rather than providing proof of efficacy in humans.

Next, the team plans to test this approach in models that more closely reflect disease conditions while carefully assessing safety. HLA-E is also present in healthy tissues, and removing its protective signal could affect the balance between normal cells and the immune system. Whether this strategy can enhance the clearance of diseased cells while preserving healthy tissues will determine how far it remains from clinical application.

References

  1. Duke University School of Medicine
  2. PubMed / National Library of Medicine
  3. Scholars@Duke